{
    "nct_id": "NCT04306900",
    "official_title": "Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination With Pembrolizumab or Budigalimab and/or Chemotherapy in Subjects With Advanced Solid Tumors",
    "inclusion_criteria": "1. Age 18 years or older, is willing and able to provide informed consent\n2. Histologically confirmed diagnosis of unresectable or metastatic solid tumor malignancy in selected tumor types\n3. Life expectancy > 12 weeks\n4. ECOG performance status of 0-1\n\nAbbreviated\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 110 Years",
    "exclusion_criteria": "1. History of allergy or hypersensitivity to study treatment components. Patients with a history of severe hypersensitivity reaction to any monoclonal antibody.\n2. Use of investigational agent within 28 days prior to the first dose of study treatment and throughout the study\n3. Receiving high-dose systemic steroid therapy or any other form of immunosuppressive therapy\n4. History of severe autoimmune disease\n5. Uncontrolled intercurrent illness or other active malignancy requiring ongoing treatment",
    "miscellaneous_criteria": "Abbreviated"
}